Valentyn Oksenych, PhD

Home page

  • Valentyn Oksenych, PhD

    lab.oksenych@gmail.com

    Academic interests

    DNA in our cells is constantly damaged by various internal and external factors. To maintain genomic stability, the cells develop multiple DNA repair pathways. Mutations in DNA repair genes lead to disorders in humans. Non-Homologous End-Joining (NHEJ) fixes the DNA double-strand breaks (DSB) throughout the cell cycle. NHEJ is required for the development of immune and nervous systems and to suppress medulloblastoma.

    NHEJ consists of Ku70, Ku80, XLF, XRCC4, DNA Ligase 4, DNA-PKcs, Artemis, XLS/PAXX, APLF, Mri/Cyren. There is a complex genetic interaction between the NHEJ factors (eg, Oksenych et al., PNAS, 2013; Xing et al., DNA repair, 2017; Castaneda-Zegarra et al., DNA repair, 2019; Xing and Oksenych, FEBS open bio, 2019; Castaneda-Zegarra et al., Aging, 2020; Castaneda-Zegarra et al., Scandinavian Journal of Immunology, 2020).

    In response to DNA damage, there is a complex process that includes the activation of multiple enzymes and modifications of proteins, such as histones surrounding the DSBs. This process is called the DNA damage response (DDR) pathway. It is facilitated by protein kinases ATM and DNA-PKcs, scaffold proteins MDC1 and 53BP1, ubiquitin-ligases RNF8 and RNF168, and many other proteins. During the DDR, histones are phosphorylated, ubiquitylated, methylated, acetylated, SUMOylated, NEDDylated, etc (Zha et al., Nature, 2011; Oksencyh et al., PNAS, 2012; Kumar et al., DNA repair, 2014; Beck et al. al., Biomolecules, 2020). I am attempting to understand the complexity of DDR, as well as its role in the development of the immune system and in cancer suppression.

    Both NHEJ and DDR pathways are involved in immune system development, including the V(D)J recombination in developing B and T lymphocytes, and the Class Switch Recombination (CSR) in mature B cells.

    Translocations associated with V(D)J recombination and class switch recombination (CSR) can be detected using High Throughput Genome-Wide Translocation sequencing (HTGTS). I collaborate with researchers at Karolinska Institutet and Harvard Medical School to develop HTGTS-based assays using primary human B cells.

    Several drug candidates were identified to be used in cancer and immune disease treatments. I collaborate with researchers at UiO and local hospitals to validate and select the best options for further translation to the clinic. 

    Background

    2023-2025. Researcher. University of Bergen, Bergen, Norway

    2015-2022. Researcher, principal investigator. NTNU – Trondheim, Norway

    2021-2022. Lecturer. University of Stavanger, Stavanger, Norway

    2020-2022. Researcher. University of Oslo, Oslo, Norway

    2020-2020. Researcher. The Arctic University of Norway – Tromsø (UiT)

    2018-2020. Visiting Researcher. Karolinska Institutet, Sweden

    2014-2015. Postdoc. University of Copenhagen, Denmark

    2010-2014. Postdoc. Harvard Medical School, USA

    2005-2009. PhD candidate. IGBMC, University of Strasbourg, France

    Past projects and awards (ca. 3 M€)

    2020-2021. Karolinska Institutet (KI Foundations and Funds). #2020-02155

    2020-2021. Health Authority of Central Norway. #38811

    2019-2022. Award in innovation, enabling technologies, NTNU, Norway

    2018-2019. NTNU PES and POS grants, Norway

    2018-2019. Research Council of Norway, FRIPRO. #291217

    2017-2021. Outstanding Academic Fellow Award, NTNU, Norway

    2017-2020. Norwegian Cancer Society, Open call. #182355

    2016-2019. Research Council of Norway, FRIMEDBIO. #249774

    2016-2018. Research Council of Norway, FRIPRO. #270491

    2016-2018. Health Authority of Central Norway. #13477

    2015-2017. Lundbeck Fellowship, University of Copenhagen, Denmark

    2008-2009. Anti-Cancer Research Association (ARC), France

    2007-2008. Anti-Cancer Research Association (ARC), France

    2005. Mobility grant, IBB – Academy of Science, Warsaw, Poland

    Keywords: B cells, DNA repair, mouse models, Genetics, Immunology

    Alumni (Oksenych group, NTNU)

    Graduated PhD students:

    1. Mengtan Xing (2016-2019)

    2. Sergio Miguel Castaneda-Zegarra (2019-2022)

    Graduated MSc students:

    3. Alisa Dewan (2016-2017)

    4. Siri Sæterstad (2016-2018)

    5. Phong Chau (2016-2018)

    6. Camilla Huse (2017-2019)

    7. Øystein Røsand (2017-2019)

    8. Sergio Miguel Castaneda-Zegarra (2018-2019; enrolled in Bergen-UiB and Trondheim-NTNU)

    9. Amin Alirezaylavasani (2018-2020)

    10. Qindong Zhang (2018-2020)

    11. Kalaiyarasi Ragunathan (2018-2020)

    Visiting students:

    12. Kimiko Teyama (てやまんぬ, MD student, Japan; 2017)

    13. Julia Werner (Erasmus student, Heidelberg University, Germany; 2019)

    14. Max Tkachov (MSc student, NTNU, Norway; 2019-2020)

    Postdocs:

    15. Raquel Gago-Fuentes (2016-2018)

    16. Carole Beck (2017-2020)

    Research assistants:

    17. Stefano Bradamante (2016-2017)

    18. Nikki Upfold (2019-2020)

    Commissions of trust

    Reviewer (78 journals; 269 reviews).

    Aging (4); AITE (1); Antioxidants (8); BBA-MCR (1); Biology (2); Biomarker Insights (2); Biomed Research International (2); Biomedical Journal (1); Biomedicine & Pharmacotherapy (3); Biomedicines (6); Biomolecules (12); Bioorganic Chemistry (1); BMJ Public Health (1); Cancers (32); Carcinogenesis (1); Cell cycle (5); Cells (10); Cellular and Molecular Life Sciences (3); Clinical and Translational Discovery (1); Computational and Structural Biotechnology J (1); Coronaviruses (3); Current Oncology (1); Cytometry Part A (2); Endocrine Regulations (1); Experimental and Therapeutic Medicine (1); FEBS journal (8); FEBS Open Bio (10); Frontiers in Bioengineering and Biotechnology (1); Frontiers in Bioscience-Landmark (1); Frontiers in Cell and Developmental Biology (4); Frontiers in Genetics (1); Frontiers in Immunology (8); Frontiers in Medicine (1); Frontiers in Microbiology (4); Frontiers in Microbiomes (1); Frontiers in Molecular Biosciences (3); Frontiers in Oncology (4); Frontiers in Pharmacology (1); Frontiers in Public Health (1); Gene expression (1); Genes (1); Genomics (6); IJBIOMAC (2); IJMM (2); IJMS (40); International Journal of Oncology (1); Journal of Cellular Physiology (2); Journal of Immunological Methods (1); Journal of Personalized Medicine (1); JoVE (1); LabMed (1); Life (2); Life Sciences (3); Medicine (1); Metabolites (1); Microorganisms (3); Mini-Reviews in Medicinal Chemistry (1); Molecular Medicine Reports (1); Molecular Neurobiology (1); Molecules (2); NAR (5); NeuroSci (1); Oncology Letters (5); Oncology Reports (2); Oxidative Medicine and Cellular Longevity (2); Phytomedicine (4); PLOS One (2); PLOS Pathogens (1); Process Biochemistry (1); Recent Patents on Biotechnology (2); Reproduction (2); Rheumato (1); Scientific Reports (3); Toxicology in vitro (1); Toxicology research (1); Vaccines (2); Viruses (2); Virology Journal (1); World Academy of Sciences Journal (1).

    WoS profile: https://www.webofscience.com/wos/author/record/1501536

    Editor (10 journals; 3EB, editorial board; 7 AE, academic editor).

    • Biomolecules (2019-now; EB, AE, guest editor).
    • Frontiers in Bioscience (2021-2022; EB).
    • Frontiers in Bioengineering-and-Biotechnology (2020-now; AE).
    • Frontiers in Endocrinology (2023-now; AE).
    • Frontiers in Immunology (2021-now; AE, guest editor).
    • Frontiers in Microbiology (2018-now; AE).
    • Frontiers in Oncology (2021-2023; AE, guest editor).
    • Frontiers in Pediatrics (2021; AE).
    • Microbes&Immunity (2023-now; EB).
    • Viruses (2021-2023; AE, guest editor).

    Advisory Board

    Preprints.org (2023-now)

    Grant evaluation (166, in 8 countries, for 10 agencies; 2017-2025).

    MSc graduation committee (2, in Norway).

    • NTNU, Norway. Internal sensor: Aliaksandr Maisiuk (2020);
    • NTNU, Norway. Internal sensor: Klara Krpina (2020).

    PhD graduation committee (4, in 3 countries).

    • NTNU, Norway: Karine Bjørås (2017; administrator, third opponent)
    • NTNU, Norway: Katarzyna Anna Baranowska (2018; dispute leader)
    • Institute Pasteur, France: Wenming Wei (2020; external sensor)
    • Pondicherry University, India: Muthaiyan Mathavan (2021; external sensor)

    INVITED LECTURES (27)

    • 2024.  University of Oslo, Ahus, Lorenskog Campus, Norway (March)
    • 2023: University of Bergen-Broegelmann Research Laboratory (September 6)
    • 2023: University of Oslo, NCMM (June, online)
    • 2023:  Arctic University of Norway, UiT – Tromsø, Norway (february, online)
    • 2022:  NMBU, Ås, Norway
    • 2022:  Arctic University of Norway, UiT – Tromsø, Norway (June, online)
    • 2022:  University of Stavanger, Norway (June)
    • 2022:  University of Oslo, Norway (June)
    • 2022:  University of Tartu, Estonia (April, online)
    • 2022:  University of Stavanger, Norway (March, online)
    • 2021:  University of Oslo, Norway (February)
    • 2021:  University of Oslo, Norway
    • 2020: University of Oslo, Norway (online)
    • 2020:  UiT The Arctic University of Norway, Tromsø, Norway
    • 2019:  University of Aarhus, Denmark
    • 2019:  Pasteur Institute, Paris, France
    • 2019:   University of Innsbruck, Austria
    • 2019:  University of Helsinki, Finland
    • 2018:  University of Tartu, Estonia
    • 2018:  Karolinska Institutet, Sweden
    • 2018:  University of Oslo, Norway
    • 2016:  European Commission, interview for ERC grant, Brussels, Belgium
    • 2016:  University of Helsinki, Biomedicum Helsinki Seminar, Finland
    • 2009:  University of Stanford (2 times, September)
    • 2009:  Harvard Medical School (October)
    • 2009:  Harvard Medical School (September)

    CONFERENCE TALKS (13)

    • 2021:  Biotechnology seminar NTNU, Trondheim, Norway
    • 2019:  Scandinavian Society for Immunology-SSI meeting, Geilo, Norway
    • 2019:  First Immunology and Infection meeting, Berlin, Germany
    • 2017:  Molecular mechanisms underlying carcinogenesis and neurodegeneration, Trondheim, Norway
    • 2017:  DNA and RNA dynamics workshop (organizer, chairman, speaker), Trondheim, Norway
    • 2017:  Norwegian Biochemical Society meeting, Oppdal, Norway
    • 2017:  Norwegian Biochemical Society Annual meeting, Storfjell, Norway
    • 2016:  DNA repair, Epigenetics, and Translational Medicine, Trondheim, Norway
    • 2016:  Norwegian Biochemical Society meeting, Åre, Sweden
    • 2016:  Norwegian Biochemical Society Annual Meeting, Tromsø, Norway
    • 2015:  Tomas Lindahl conference on DNA Repair, Oslo, Norway
    • 2008:  DNA repair meeting, Porto, Portugal
    • 2007:  DNA repair meeting, Sicily, Italy

    Social media and research profiles

    Twitter: https://twitter.com/oksenych

    LinkedIn: https://www.linkedin.com/in/oksenych/

    Facebook: https://www.facebook.com/DNArepairNHEJ

    Youtube: https://www.youtube.com/channel/UCXy_OvlRYdZ1AwjIrIDw8OA

    Research gate: https://www.researchgate.net/profile/Valentyn-Oksenych

    Scopus: https://www.scopus.com/authid/detail.uri?authorId=16242096600

    ORCID: https://orcid.org/0000-0002-5088-3791

    Sci Profiles: https://sciprofiles.com/profile/oksenych

    Frontiers Loop: https://loop.frontiersin.org/people/695622/overview

    Web of Science: https://www.webofscience.com/wos/author/record/1501536

    wikipedia: https://no.wikipedia.org/wiki/Valentyn_Oksenych

    Publications and metrics

    130 published papers (2007-2025), including 14 as a first/co-first and 89 as a senior/*corresponding author. The h-index: 31, i10-index: 71; the total number of citations: 3893 (Google Scholar, October 2025).

    I have published in Nature (1), Molecular Cell (2), NAR (1), EMBOj (1), PNAS (3), JI (1), CMLS (2), PLOS Genetics (1), Aging (1); DNA repair (4), Cell Cycle (1), etc.

    Pubmed: https://pubmed.ncbi.nlm.nih.gov/?term=oksenych

    Google Scholar: https://scholar.google.com/citations?user=u9FJXScAAAAJ

    130. Kamyshnyi O, Kamyshna I, Petakh P, Halabitska I, Bjoras M, Oksenych V, Schoving MP, Kainov DE (2025). Towards molecular diagnostics of parental alienation. CMLS (Accepted)

    129*. Naderian R, Paraandavaji E, Maddah AH, Keshavarzi S, Habibian A, Naderian R, Hosseini SM, Oksenych V*, Eslami M. (2025). Pathophysiology and Clinical Implications of Dengue-Associated Neurological Disorders. Frontiers in Microbiology. doi: 10.3389/fmicb.2025.1536955

    128*. Bahar A, Parsasefat M, Khazaei M, Tahmasebi H, Oksenych V* (2025) Effect of Nematodes-Bacteria Complex Metabolites on Cancer and Tumor Progression. Biomolecules 15(8), 1165; https://doi.org/10.3390/biom15081165

    127*. Oksenych V*, Petakh P, Kainov D, Kamyshnyi O. (2025). A CRISPR-Cas9-based tool for dose-dependent DNA damage detection. FEBS journal https://doi.org/10.1111/febs.70186

    126*. Pazoki A, Dadfar S, Alirezaee A, Oksenych V*, Haghmorad D (2025). Lung Cancer Vaccine Strategies: Exploring the Spectrum from Traditional to RNA-Based Platforms. Frontiers in Bioengineering and Biotechnology. https://doi.org/10.3389/fbioe.2025.1617352

    125*. Popazova O, Belenichev I, Bukhtiyarova N, Ryzhenko V, Gorchakova N, Oksenych V*, Kamyshnyi O (2025). Molecular and biochemical mechanisms of cardiomyopathy development following prenatal hypoxia – focus on the NO system. Antioxidants 2025, 14(6), 743; https://doi.org/10.3390/antiox14060743

    124*. Kamalabadi-Farahani M, Bahar A, Tahmasebi H, Oksenych V*, Jahantigh M (2025). Microbial Metabolite Effects on Vasculogenic Mimicry in Metastatic Cancers. Cells 2025 14(11), 811; https://doi.org/10.3390/cells14110811

    123*. Sokolenko M, Sydorchuk L, Sokolenko A, Sydorchuk R, Kamyshna I, Sydorchuk A, Sokolenko L, Sokolenko O, Oksenych V*, Kamyshnyi O (2025). Antiviral intervention of COVID-19: linkage of disease severity with genetic markers FGB (rs1800790), NOS3 (rs2070744) and TMPRSS2 (rs12329760). Viruses 2025 17(6), 792; https://doi.org/10.3390/v17060792

    122*. Eslami M, Dowlat BF, Yaghmayee S, Habibian A, Keshavarzi S, Oksenych V*, Naderian R (2025). Next-Generation vaccine platforms: integrating synthetic biology, nanotechnology, and systems immunology for improved immunogenicity. Vaccines 2025, 13(6), 588; https://doi.org/10.3390/vaccines13060588

    121*. Antypenko L, Shabelnyk K, Antypenko O, Arisawa M, Kamyshnyi O, Oksenych V*, Kovalenko S (2025). In silico identification and characterization of spiro[1,2,4]triazolo[1,5-c]quinazolines as diacylglycerol kinase α modulators. Molecules 2025, 30(11), 2324; https://doi.org/10.3390/molecules30112324

    120*. Lohvinenko N, Shvets V, Antypenko O, Voskoboinik O, Bozhkov A, Maslak H, Oksenych V*, Kamyshnyi O, Okovytyy S, Kovalenko S (2025). Application of S-substituted pteridine for acute hepatitis treatment in rats. Biomedicines 2025, 13(6), 1276; https://doi.org/10.3390/biomedicines13061276

    119*. Nouri F, Alibabaei F, Foroozanmehr B, Tahmasebi H, Oksenych V*, Eslami M (2025). Progress in CRISPR Technology for Antiviral Treatments: Genome Editing as a Potential Cure for Chronic Viral Infections. Microbiol. Res. 2025, 16(5), 104; https://doi.org/10.3390/microbiolres16050104

    118*. Halabitska I, Petakh P, Oksenych V*, Kamyshnyi O. (2025) Reactivation of Latent Tuberculosis in a Patient with COVID-19 and Epstein-Barr Virus Coinfection: A Case Report. Pathogens 2025, 14(5), 488; https://doi.org/10.3390/pathogens14050488

    117*. Zhang J, Zhao Q, Sun Q, Jiang H, Oksenych V*, Wang X (2025). Editorial: Enhancing T Cell Function: Innovations in Cancer Immunotherapy. Frontiers in Immunology 2025 Accepted

    116. Ravlo E, Ianevski A, Skipperstøen MN, Lysvand H, Schjølberg JO, Solheim JO, Wang W, Kissova M, Vestvik M, Vapalahti O, Smura T, Vauhkonen H, Oksenych V, Weber F, Strand M, Evander M, Malmring JF; Afset JE, Bjørås M, Kainov DE (2025). JAK inhibitors remove innate immune barriers, facilitating viral propagation. NAR Mol Med 2025 Accepted

    115*. Eslami M, Naderian R, Bahar A, Babaeizad A, Gheshlagh SR, Oksenych V*, Tahmasebi H. (2025) Microbiota as diagnostic biomarkers: advancing early cancer detection and personalized therapeutic approaches through microbiome profiling. Frontiers in Immunology 2025 Accepted

    114*. Nemati MH, Yazdanpanah E, Kazemi R, Orooji N, Dadfar S, Oksenych V*, Haghmorad D* (2025). Microbiota-Driven Mechanisms in Multiple Sclerosis: Pathogenesis, Therapeutic Strategies, and Biomarker Potential. Biology 2025 (Accepted)

    113*. Aliyeva OG, Belenichev IF *, Bilai I, Duiun I, Makyeyeva L, Oksenych V*, Kamyshnyi O (2025). The HSP70 Modulators in the Correction of Cognitive, Mnemonic, and Behavioral Disorders after Prenatal Hypoxia. Biomedicines (Accepted)

    112*. Duve K, Shkrobot S, Petakh P, Oksenych V*, Kamyshnyi O (2025). Some Prognostic Markers for Cognitive and Functional Outcomes AfterTraumatic Brain Injury. JCM 2025 (Accepted)

    111*. Buchynskyi, Kamyshna I, Halabitska I, Petakh P, Oksenych V*, Kamyshnyi O (2025). Genetic Predictors of Paxlovid Efficacy: The Role of IFNAR2, OAS1, OAS3, and ACE2 in COVID-19 Clinical Course. JPM 2025 (Accepted)

    110*. Buchynskyi M, Kamyshna I, Halabitska I, Petakh P, Kunduzova O, Oksenych V*, Kamyshnyi O (2025). Unlocking the Gut-Liver Axis: Microbial Contributions to the Pathogenesis of Metabolic-Associated Fatty Liver Disease. Frontiers in Microbiology https://doi.org/10.3389/fmicb.2025.1577724

    109*. Eslami M, Dowlat BF, Yaghmayee S, Tabaei FM, Oksenych V*, Naderian R. (2025). A Novel Frontier in Gut-Brain Axis Research: The Transplantation of Fecal Microbiota in Neurodegenerative Disorders. Biomedicines 2025, 13(4), 915; https://doi.org/10.3390/biomedicines13040915

    108*. Khazaei M, Parsasefat M, Bahar A, Tahmasebi H, Oksenych V*. (2025). Behavioral cooperation or conflict of human intestinal round-worms and microbiomes: A Bio-activity Perspective in Human. Cells 2025, 14(7), 556; https://doi.org/10.3390/cells14070556

    107. Petakh P, Oksenych V, Kamyshnyi O. (2025). Prevalence of leptospirosis among soldiers: A systematic review. 2025 PLoS Negl Trop Dis. 2025 Mar 17;19(3):e0012927. doi: 10.1371/journal.pntd.0012927

    106*. Salnykov V, Belenichev I, Makyeyeva L, Skoryna D, Oksenych V*, Kamyshnyi O. (2025). Antioxidant Mechanisms of the Protective Action of Selenase in Experimental Chronic Generalized Periodontitis. CIMB 2025, 47(3), 186; https://doi.org/10.3390/cimb47030186

    105*. Eslami M, Arjmand N, Mahmoudian F, Babaeizad A, Tahmasebi H, Fattahi F, Oksenych V*. (2025). Deciphering Host-Virus Interactions and Advancing Therapeutics for Chronic Viral Infection. Viruses 2025, 17(3), 390; https://doi.org/10.3390/v17030390

    104*. Nashtahosseini Z, Eslami M, Paraandavaji E, Haraj A, Dowlat BF, Hosseinzadeh E, Oksenych V*, Naderian R. (2025) Cytokine Signaling in Diabetic Neuropathy: A Key Player in Peripheral Nerve Damage. Biomedicines 2025, 13(3), 589; https://doi.org/10.3390/biomedicines13030589

    103*. Haghmorad D, Eslami M, Orooji N, Halabitska I, Kamyshna I, Kamyshnyi O, Oksenych V*. (2025) mRNA vaccine platforms: Linking infectious disease prevention and cancer immunotherapy Accepted, Frontiers in Bioengineering and Biotechnology 2025 doi: 10.3389/fbioe.2025.1547025

    102*. Eslami M, Nazari MA, Azami MH, Rad PS, Oksenych V*, Naderian R. (2025). The Anti-inflammatory Potential of Tricyclic Antidepressants (TCA): A Novel Therapeutic Approach to Atherosclerosis Pathophysiology. Submitted to Pharmaceuticals 2025, 18(2), 197; https://doi.org/10.3390/ph18020197

    101*. Eslami M, Banihashemian SZ, Niaragh SN, Hemmati MA, Shojaeian A, Fakhariyan S, Rabbani A, Oksenych V*. (2025) Innovative antibiotic therapies for carbapenem-resistant Gram-negative bacterial infections: clinical efficacy, safety, and comparative studies. Microorganisms 2025, 13(2), 295; https://doi.org/10.3390/microorganisms13020295

    100*. Belenichev I, Popazova O, Bukhtiyarova N, Ryzhenko V, Pavlov SV, Suprun E, Oksenych V*, Kamyshnyi O. (2025) Mitochondrial dysfunction in cerebral ischemia and pharma-cologic approaches to its correction. Antioxidants 2025, 14(1), 108; https://doi.org/10.3390/antiox14010108

    99*. Belenichev I, Popazova O, Yadlovskyi O, Bukhtiyarova N, Ryzhenko V, Pavlov SV, Oksenych V*, Kamyshnyi O. (2025) Possibility of using NO modulators for pharmacocorrection of endothelial dysfunction after prenatal hypoxia. Pharmaceuticals 2025, 18(1), 106; https://doi.org/10.3390/ph18010106

    98*. Shabelnyk K, Fominichenko A, Antypenko O, Gaponov O, Kopteva S, Shyshkina S, Voskoboinik O, Okovytyy S, Kovalenko S, Oksenych V*, Kamyshnyi O. (2025) [2-(3-R-1H-[1,2,4]-triazol-5-YL)phenyl]amines: design, synthesis, and assessment of their anti-staphylococcal potential. Pharmaceuticals 2025 , 18(1), 83; https://doi.org/10.3390/ph18010083

    97*. Tahmasebi H, Arjmand N, Monemi M, Babaeizad A, Alibabaei F, Alibabaei N, Bahar A, Oksenych V*, Eslami M. (2025). From Cure to Crisis: Understanding the Evolution of Antibiotic-Resistant Bacteria in Human Microbiota. Biomolecules 2025, 15(1), 93; https://doi.org/10.3390/biom15010093

    96*. Escandari T, Eivazzadeh Y, Khaleghinia F, Kashi F, Oksenych V*, Haghmorad D. (2025). Lipid Antigens: Revealing the Hidden Players in Adaptive Immune Responses. Biomolecules 2025, 15(1), 84; https://doi.org/10.3390/biom15010084

    95. Ravlo E, Ianevski A, Schjølberg J, Solvang V, Dumaru R, Lysvand H, Hankinson J, Vähä-Koskela M, Vainionpää S, Varhe A, Seppänen H, Smura T, Wang X, Wang Y, Li P, Pan Q, Dahl-Jorgensen K, Krogvold L, Kamyshnyi O, Nilsen HJS, Haugen IJ, Høyer E, Afset JE, Oksenych V, Galabov AS, Stoyanova A, Lam V, van Loon B, Lulla V, Bjørås M, Kainov DE (2025). Synergistic combination of orally available safe-in-man pleconaril, AG7404, and mindeudesivir inhibits broad range of enterovirus infections. CMLS 2025, 23;82(1):57. doi: 10.1007/s00018-025-05581-4.

    94*. Karbalaei M, Esmailpour M, Eslami M, and Oksenych V*. (2025) Comprehensive analysis of blaCTX-M1 gene expression alongside iutA, csgA, and kpsMII virulence genes in septicemic Escherichia coli using real-time PCR. Microorganisms 2025, 13(1), 95; https://doi.org/10.3390/microorganisms13010095

    93*. Halabitska I, Petakh P, Lushchak O, Kamyshna I, Oksenych V*, Kamyshnyi O. (2024). Metformin in Antiviral Therapy: Evidence and Perspectives. Viruses 2024, 16(12), 1938; https://doi.org/10.3390/v16121938

    92*. Rad HF, Tahmasebi H, Javani S, Hemati M, Zakerhamidi D, Hosseini M, Alibabaei F, Banihashemian SZ, Oksenych V*, Eslami M. (2024). Microbiota and Cytokine Modulation: Innovations in Enhancing Anticancer Immunity and Personalized Cancer Therapies. Biomedicines 2024, 12(12), 2776; https://doi.org/10.3390/biomedicines12122776

    91*. Hemmati MA, Asli S, Mohammadi S, Forouzanmehr B, Haghmorad D, Oksenych V*, Eslami M. (2024) Using New Technologies to Analyze Gut Microbiota and Predict Cancer Risk. Cells 2024, 13(23), 1987; https://doi.org/10.3390/cells13231987

    90*. Yazdanpanah E, Pazoki A, Dadfar S, Nemati MH, Tarahomi M, Orooji N, Haghmorad D, Oksenych V*. (2024) Interleukin-27 and Autoimmune Disorders: A Compressive Review of Immunological Functions. Biomolecules 2024, 14(12), 1489; https://doi.org/10.3390/biom14121489

    89*. Yousefi B, Kashanipoor S, Mazaheri P, Alibabaei F, Babaeizad A, Asli S, Mohammadi S, Gorgin AH, Alipour T, Oksenych V*, Eslami M. (2024) Cefiderocol and Its Role in Combating Carbapenem-Resistant Acinetobacter baumannii: Mechanisms of Action and Resistance. Biomedicines 2024, 12(11), 2532; https://doi.org/10.3390/biomedicines12112532

    88*. Grytsak О, Schabelnyk К, Severina HI, Ryzhenko V, Voskoboynik O, Belenichev I, Kovalenko SS, Oksenych V*, Kamyshnyi O. (2024) Bioisosteric replacement in the search for biologically active compounds: design, synthesis and anti-inflammatory activity of novel [1,2,4]triazino[2,3-c]quinazolines. Pharmaceuticals 2024, 17(11), 1437; https://doi.org/10.3390/ph17111437

    87*. Eslami M, Alibabaei F, Babaeizad A, Banihashemian SZ, Mazandarani M, Hoseini A, Ramezankhan M, Oksenych V*, Yousefi B. (2024) The Importance of Gut Microbiota on Choline Metabolism in Neurodegenerative Diseases. Biomolecules 2024, 14(11), 1345; https://doi.org/10.3390/biom14111345

    86*. Halabitska I, Petakh P, Oksenych V*, Kamyshnyi O. (2024) Predictive Analysis of Osteoarthritis and Chronic Pancreatitis Comorbidity: Complications and Risk Factors. Front. Endocrinol. doi: 10.3389/fendo.2024.1492741

    85. Halabitska I, Petakh P, Kamyshna I, Oksenych V, Kainov DE, Kamyshnyi O. (2024) The Interplay of Gut Microbiota, Obesity, and Depression: Insights and Interventions. CMLS 2024 Oct 30;81(1):443. doi: 10.1007/s00018-024-05476-w.

    84*. Halabitska I, Oksenych V*, and Kamyshnyi O. (2024). Exploring the Efficacy of Alpha-Lipoic Acid in Comorbid Osteoarthritis and Type 2 Diabetes Mellitus. Nutrients 2024, 16(19), 3349; https://doi.org/10.3390/nu16193349

    83*.  Belenichev I, Bukhtiyarova N, Ryzhenko V, Makyeyeva L, Morozova O, Oksenych V*, Kamyshnyi O. (2024). Methodological approaches to experimental evaluation of neuroprotective action of potential drugs. IJMS 2024 25(19), 10475; https://doi.org/10.3390/ijms251910475

    82*. Dadfar S, Yazdanpanah E, Pazoki A, Nemati MH, Eslami M, Haghmorad D, Oksenych V*. The Role of Mesenchymal Stem Cells in Modulating Adaptive Immune Responses in Multiple Sclerosis. Cells 2024, 13(18), 1556; https://doi.org/10.3390/cells13181556

    81*. Gharibi S, Moghimi B, Mahmoudi MB, Shahvazian E, Yazd EF, Yadegari M, Haghmorad D, Oksenych V*. (2024). Dysregulation of miR-223, miR-146a, and miR-193a expression profile in acute and chronic phases of experimental autoimmune encephalomyelitis in C57BL/6 mice. Cells 2024, 13(17), 1499; https://doi.org/10.3390/cells13171499

    80#. Du L#, Oksenych V#, Wan H, Ye X, Dong J, Ye AY, Abolhassani H, Zhang X, de la Rosa K, Hammarström L, van der Burg M, Alt FW, Pan-Hammarström Q. (2024). Unbiased profiling of immunoglobulin class switch recombination in human B cells. J Immunol. 2024 Sep 9:ji2300842. doi: 10.4049/jimmunol.2300842.

    79*. Belenichev I, Goncharov O, Bukhtiyarova N, Kuchkovskyi O, Ryzhenko V, Makyeyeva L, Oksenych V*, and Kamyshnyi O. (2024). Comparative analysis of the effect of beta blockers of different generations on the parameters of myocardial energy metabolism in experimental doxorubicin-induced chronic heart failure. Biomedicines 2024, 12(9), 1957; https://doi.org/10.3390/biomedicines12091957

    78*. Buchynskyi M, Oksenych V*, Kamyshna I, Budarna O, Kamyshnyi O. (2024) Genomic Insight into the COVID-19 Severity in MAFLD Patients: a Single-Center Prospective Cohort Study. Frontiers in Genetics (Accepted)

    77*. Pazoki A, Dadfar S, Shadab A, Haghmorad D, Oksenych V*. (2024) Soluble CD40 Ligand as a Promising Biomarker in Cancer Diagnosis. Cells 2024, 13(15), 1267; https://doi.org/10.3390/cells13151267

    76*. Petakh P, Poliak M, Kohutych A, Oksenych V*, Kamyshnyi O. (2024) Impact of Antibiotic and Steroid Therapy on Leptospirosis Outcomes: A Retrospective Cohort Study in Transcarpathia, Ukraine. Biomedicines 2024, 12(8), 1685; https://doi.org/10.3390/biomedicines12081685

    75*. Belenichev I, Aliyeva O, Burlaka B, Burlaka K, Kuchkovskyi O, Savchenko D, Oksenych V*, Kamyshnyi O. (2024) Development and optimization of nasal composition of a neuroprotective agent for use in neonatology after prenatal hypoxia. Pharmaceuticals 2024, 17(8), 990; https://doi.org/10.3390/ph17080990

    74*. Petakh P, Oksenych V*, Kamyshnyi O. (2024) Corticosteroid treatment in leptospirosis: a systematic review and meta-analysis. J. Clin. Med. 2024, 13(15), 4310; https://doi.org/10.3390/jcm13154310

    73*. Halabitska I, Babinets L, Oksenych V*, and Kamyshnyi O. (2024) Diabetes and Osteoarthritis: Exploring the Interactions and Therapeutic Implications of Insulin, Metformin, and GLP-1-Based Interventions. Biomedicines 2024, 12(8), 1630; https://doi.org/10.3390/biomedicines12081630

    72*. Belenichev I, Ryzhenko V, Popazova O, Bukhtiyarova N, Gorchakova N, Oksenych V*, Kamyshnyi O. (2024). Optimization of the search for neuroprotectors among bioflavonoids. Pharmaceuticals 2024, 17(7), 877; https://doi.org/10.3390/ph17070877

    71*. Buchynskyi M, Oksenych V*, Kamyshna I, Vorobets I, Halabitska I, Kamyshnyi O. (2024). Modulatory Roles of AHR, FFAR2, FXR, and TGR5 Gene Expression in Metabolic-Associated Fatty Liver Disease and COVID-19 Outcomes. Viruses. 2024 Jun 19;16(6):985. doi: 10.3390/v16060985.

    70*. Petakh P, Oksenych V*, Khovpey Y, Kamyshnyi O. (2024). Comprehensive Analysis of Antiphage Defense Mechanisms: Serovar-Specific Patterns. Antibiotics (Basel). 2024 Jun 3;13(6):522. doi: 10.3390/antibiotics13060522.

    69*. Haghmorad D, Oksenych V*, Huszthy PC. (2024). EDITORIAL: Exploring the role of T helper cells in autoimmune disease. Frontiers in Immunology. 2024 Jun 4;15:1434684. doi: 10.3389/fimmu.2024.1434684. eCollection 2024.

    68*. Petakh P, Kamyshnyi O, Duve K, Oksenych V*, Behzadi P. (2024) Molecular Mechanisms and Therapeutic Possibilities of Short-Chain Fatty Acids in Posttraumatic Stress Disorder Patients: A Mini-Review. Frontiers in Neuroscience. 2024 Jun 3;18:1394953. doi: 10.3389/fnins.2024.1394953. eCollection 2024.

    67*. Petakh P, Behzadi P, Oksenych V*, Kamyshnyi O. (2024) Current Treatment Options for Leptospirosis: A Mini-Review. Frontiers in Microbiology. 2024 Apr 25;15:1403765. doi: 10.3389/fmicb.2024.1403765. eCollection 2024.

    66*. Belenichev I, Popazova O, Bukhtiyarova N, Savchenko D, Oksenych V*, Kamyshnyi O. (2024) Nitric oxide in the mechanisms of cell death and cytoprotection. Antioxidants. 2024 Apr 23;13(5):504. doi: 10.3390/antiox13050504.

    65*. Kamenshchyk A, Belenichev I, Oksenych V*, Kamyshnyi A. (2024) Combined pharmacological modulation of translational and transcriptional activity signaling pathways as a promising therapeutic approach in children with myocardial changes. Biomolecules. 2024, 14(4), 477; https://doi.org/10.3390/biom14040477

    64*. Petakh P, Oksenych V*, Kamyshnyi O. (2024) Exploring Leptospira interrogans FDAARGOS_203: Insights into AMR and Anti-phage Defense. Microorganisms. 2024, 12(3), 546; https://doi.org/10.3390/microorganisms12030546

    63. Ianevski A, Frøysa IT, Lysvand H, Calitz C, Smura T, Nilsen HJS, Høyer E, Afset JE, Sridhar A, Wolthers KC, Zusinaite E, Tenson T, Kurg R, Oksenych V, Galabov AS, Stoyanova A, Bjørås M, Kainov DE. (2024) The combination of pleconaril, rupintrivir, and remdesivir efficiently inhibits enterovirus infections in vitro, delaying the development of drug-resistant virus variants. Antiviral Research. 2024 Apr; 224:105842. doi: 10.1016/j.antiviral.2024.105842

    62*. Petakh P, Kamyshna I, Oksenych V*, Kamyshnyi O. (2024) Metformin Alters mRNA Expression of FOXP3, RORC, and TBX21 and Modulates Gut Microbiota in COVID-19 Patients with Type 2 Diabetes. Viruses. 2024, 16(2), 281; https://doi.org/10.3390/v16020281

    61. Petakh P, Oksenych V, Kamyshna I, Boisak I, Lyubomirskaya K, Kamyshnyi O. (2024) Exploring the Complex Interplay: Gut Microbiome, Stress, and Leptospirosis. Front. Microbiol. doi: 10.3389/fmicb.2024.1345684

    60. Petakh P, Oksenych V, Kamyshna I, Boisak I, Lyubomirskaya K, Kamyshnyi O. (2024) Exploring the Interplay Between Posttraumatic Stress Disorder, Gut Microbiota, and Inflammatory Biomarkers: A Comprehensive Meta-Analysis. Front. Immunol. doi: 10.3389/fimmu.2024.1349883

    59*. Buchynskyi M, Oksenych V*, Kamyshna I, Kamyshnyi O. (2024) Exploring Paxlovid Efficacy in COVID-19 Patients with MAFLD: Insights from a Single-Center Prospective Cohort Study. Viruses. 2024 Jan 12;16(1):112. doi: 10.3390/v16010112.

    58*. Popazova O, Belenichev I, Yadlovskyi O, Oksenych V*, Kamyshnyi A. (2023) Altered Blood Molecular Markers of Cardiovascular Function in Rats After Intrauterine Hypoxia and Drug Therapy. CIMB 2023, 45(11), 8704-8715; https://doi.org/10.3390/cimb45110547

    57*. Popazova O, Belenichev I, Bukhtiyarova N,Ryzhenko V, Oksenych V*, Kamyshnyi A (2023). Cardioprotective Activity of Pharmacological Agents Affecting NO Production and Bioavailability in the Early Postnatal Period after Intrauterine Hypoxia in Rats. Biomedicines 2023, 11(10), 2854; https://doi.org/10.3390/biomedicines11102854

    56. Ravlo Е, Ianevski А, Starheim Е, Wang W, Ji P, Lysvand H, Smura T, Kivi G, Voolaid ML, Plaan K, Ustav M, Ustav M Jr., Zusinaite E, Tenson T, Kurg R, Oksenych V, Walstad K, Nordbø SA, Kaarbø M, Ernits K, Bjørås M, Kainov DE, Fenstad MH. (2023). Boosted production of antibodies which neutralized different SARS-CoV-2 variants in a COVID-19 convalescent following mRNA vaccination – a case study. Int J Infect Dis. 2023 Oct 16:S1201-9712(23)00748-8. doi: 10.1016/j.ijid.2023.10.011

    55*. Kamenshchyk A, Gonchar M, Oksenych V*, Kamyshnyi A. (2023). Association of myocardial changes and gene expression of the NFATC1 and NFATC4 – calcineurin signaling pathway in children with bicuspid aortic valve. Children 2023 10(9), 1434; https://doi.org/10.3390/children10091434

    54*. Buchynskyi M, Oksenych V*, Kamyshna I, Vari SG, Kamyshnyi A (2023). Genetic Predictors of Comorbid Course of COVID-19 and MAFLD: A Comprehensive Analysis. Viruses 2023, 15(8), 1724; https://doi.org/10.3390/v15081724

    53. Petakh P, Kamyshna I, Oksenych V, Kainov D, Kamshnyi A (2023). Metformin Therapy Changes Gut Microbiota Alpha-Diversity in COVID-19
    Patients with Type 2 Diabetes: The Role of SARS-CoV-2 Variants and Antibiotic
    Treatment.     Pharmaceuticals 2023, 16(6), 904; https://doi.org/10.3390/ph16060904

    52. Petakh P, Oksenych V, Kamyshnyi A (2023). The F/B Ratio as a Biomarker for Inflammation in COVID-19 and T2D: Impact of Metformin. Biomedicine & Pharmacotherapy 2023 Jul;163:114892. https://doi.org/10.1016/j.biopha.2023.114892

    51. Buchynskyi M, Kamyshna I, Oksenych V, Zavidniuk N, and Kamyshnyi A. (2023) The intersection of COVID-19 and MAFLD: An overview of the current evidence. Viruses 2023, 15(5), 1072; https://doi.org/10.3390/v15051072

    50. Kamyshnyi A, Koval H, Kobevko O, Buchynskyi M, Oksenych V, Kainov D, Lyubomirskaya K, Kamyshna  I, Potters G, and Moshynets O. (2023) Therapeutic Effectiveness of Interferon-α2b Against COVID-19 with community-acquired pneumonia: The Ukrainian Experience. IJMS 2023, 24(8), 6887; https://doi.org/10.3390/ijms24086887

    49*. Upfold NLE, Petakh P, Kamyshnyi A, and Oksenych V*. (2023) Tyrosine Kinase Inhibitors Target B Lymphocytes. Biomolecules 2023, 13(3), 438; https://doi.org/10.3390/biom13030438

    48*. Oksenych V*. (2023) Plasticity of Immune Cells in Tumor Microenvironment. Front Oncol. https://doi.org/10.3389/fonc.2023.1160961

    47*. Buchynskyi M, Kamyshna I, Lyubomirskaya K, Moshynets E,  Kobyliak N, Oksenych V*, Kamyshnyi A. (2023) Efficacy Of Interferon Alpha For The Treatment Of Hospitalized Patients With COVID-19: A Meta-Analysis. Front Immunol. https://doi.org/10.3389/fimmu.2023.1069894

    46*. Oksenych V*. (2022) DNA repair and immune response: Editorial. Biomolecules 2023, 13(1), 84; https://doi.org/10.3390/biom13010084

    45*. Petakh P. Isevych V. Kamyshnyi A. Oksenych V*. (2022) Weil’s Disease—Immunopathogenesis, Multiple Organ Failure, and Potential Role of Gut Microbiota. Biomolecules. 2022, 12(12), 1830; https://doi.org/10.3390/biom12121830

    44. Ianevski A, Ahmad S, Anunnitipat K, Oksenych V, Zusinaite E, Tenson T, Bjørås M, Kainov D. (2022) Seven classes of antiviral agents. CMLS. 2022, 79:605 https://doi.org/10.1007/s00018-022-04635-1

    43*. Haghmorad D, Yousefi B, Eslami M, Rashidy-Pour A, Tarahomi M, Tavaf MJ, Soltanmohammadi A, Zargarani S, Kamyshnyi A, Oksenych V*. (2022) Oral administration of Myelin Oligodendrocyte Glycoprotein attenuates experimental autoimmune encephalomyelitis through induction of Th2/Treg cells and suppression of Th1/Th17 immune responses. CIMB. 2022, 44(11), 5728-5740; https://doi.org/10.3390/cimb44110388

    42*. Kainov D, Oksenych V.* (2022) Broad-Spectrum Antivirals and Antiviral Combinations: An Editorial Update. Viruses. 2022, 14(10), 2252; https://doi.org/10.3390/v14102252

    41. Ianevski A, Zusinaite E, Tenson T, Oksenych V, Wang W, Afset JE, Bjørås M, Kainov DE. (2022) Novel synergistic anti-enteroviral drug combinations. Viruses. 2022, 14(9), 1866; https://doi.org/10.3390/v14091866

    40. Ianevski A, Simonsen RM, Myhre V, Tenson T, Oksenych V, Bjørås M, Kainov DE. (2022) DrugVirus.info 2.0: an integrative data portal for broad-spectrum antivirals (BSA) and BSA-containing drug combinations (BCCs). Nucleic Acids Research. 2022 May 24:gkac348. https://doi.org/10.1093/nar/gkac348

    39. Ianevski A, Yao R, Simonsen RM, Myhre V, Ravlo E, Kaynova GD, Zusinaite E, White JM, Polyak SJ, Oksenych V, Windisch MP, Pan Q, Lastauskienė E, Vitkauskienė A, Matukevičius A, Tenson T, Bjørås M, Kainov DE. (2022) Mono- and combinational drug therapies for global viral pandemic preparedness. iScience https://doi.org/10.1016/j.isci.2022.104112

    38*. Petakh P, Kamyshna I, Nykyforuk A, Oksenych V*, Korda M, Kamyshnyi A. (2022) Immunoregulatory intestinal microbiota and COVID-19 in patients with type two diabetes: a double-edged sword. Viruses. Feb 25;14(3):477. https://doi.org/10.3390/v14030477

    37. Oksenych V, Kainov DE. (2022). Editorial: Broad-spectrum Antivirals and Antiviral Drug Combinations. Viruses. 2022 Feb 1;14(2):301. https://doi.org/doi:10.3390/v14020301

    36*. Oksenych V*, Dan Su, Daniel JA. (2021). Acetyltransferases GCN5 and PCAF Are Required for B Lymphocyte Maturation in Mice. Biomolecules. 12(1), 61 https://doi.org/10.3390/biom12010061.

    Editor’s Choice Article 2022. Read it here: https://doi.org/10.3390/biom12010061.

    35*. Oksenych V*, and Kainov D. (2021) Editorial: DNA Damage Response. Editorial. Biomolecules Jan 19;11(1),123; https://doi.org/10.3390/biom11010123

    34. Ianevski A, Yao R, Zusinaite E, Lello LS, Wang S, Jo E, Yang J, Lysvand H, Løseth K, Oksenych V, Tenson T, Windisch MP, Poranen M, Nieminen AI, Nordbø SA, Fenstad MH, Grødeland G, Aukrust P, Trøseid M, Kantele A, Lastauskiene E, Vitkauskiene A, Legrand N, Merits A, Bjørås M, Kainov D. (2021) Synergistic interferon alpha-based antiviral combinations. Viruses https://doi.org/10.1101/2021.01.05.425331

    33. Ianevski A, Yao R, Lysvand H, Grødeland G, Legrand N, Oksenych V, Zusinaite E, Tenson T, Bjørås M,  Kainov DE. (2021) Nafamostat-interferon-alpha combination suppresses SARS-CoV-2 infection by targeting cooperatively host TMPRSS2 in vitro and in vivo. Viruses 13(9), 1768 https://doi.org/10.1101/2021.06.16.448653

    32. Ianevski A, Yao R, Zusinaite E, Lysvand H, Oksenych V, Tenson T, Bjørås M, Kainov D. (2021) Active components of commonly prescribed medicines affect influenza A virus-host cell interaction: a pilot study. Viruses 13(8), 1537; https://doi.org/10.3390/v13081537

    31*. Gago-Fuentes R., and Oksenych V.* (2020) Non-Homologous end Joining Factors XLF, PAXX and DNA-PKcs are Required to Maintain the Neural Stem and Progenitor Cell Population. Biomolecules 2021, 11(1), 20; https://doi.org/10.3390/biom11010020

          30*. Castañeda-Zegarra S, Zhang S, Alirezaylavasani A, Fernandez-Berrocal M, Yao R, and Oksenych V.* (2020) Severe immunodeficiency in mice lacking DNA repair factors XLF and Mri. Aging https://doi.org/10.18632/aging.202346

          29*. Ragunathan K, Upfold NLE, and Oksenych V*. (2020) Interaction between Fibroblasts and Immune Cells Following DNA Damage Induced by Ionizing Radiation. IJMS 21(22), 8635; https://doi.org/10.3390/ijms21228635

          28. Ianevski A, Yao R, Biza S, Zusinaite E, Männik A, Kivi G, Planken A, Kurg K, Tombak EM, Ustav M., Shtaida N, Kulesskiy E, Jo E, Yang J, Lysvand H, Løseth K, Oksenych V, Aas PA, Tenson T, Vitkauskiene A, Windisch MP, Fenstad MH, Nordbø SA, Ustav M, Bjørås M, Kainov D. (2020) Identification and tracking of antiviral drug combinations. Viruses. 12(10), 1178; https://doi.org/10.3390/v12101178

          27*. Castañeda-Zegarra S, Fernandez-Berrocal M, Tkachev M, Yao R, Upfold NLE, and Oksenych V.* (2020) Genetic interaction between the non-homologous end joining factors during B and T lymphocyte development: in vivo mouse models. Scand J Immunol. e12936. https://doi.org/10.1111/sji.12936

          26*. Beck C, Castañeda-Zegarra S, Huse C, Xing M, and Oksenych V.* (2020) Mediator of DNA Damage Checkpoint Protein 1 Facilitates V(D)J Recombination in Cells Lacking DNA Repair Factor XLF. Biomolecules 10(1), 60; https://doi.org/10.3390/biom10010060

          25. Ianevski A, Kulesskiy E, Krpina K, Lou G, Aman Y, Bugai A, Aasumets K, Akimov Y, Bulanova D, Gildemann K, Arutyunyan AF, Susova OY, Zhuze AL, Ji P, Wang W, Holien T, Bugge M, Zusinaite E, Oksenych V, Lysvand H, Gerhold JM, Bjørås M, Johansen P, Waage A, Heckman CA, Fang EF, and Kainov DE (2020). Chemical, Physical and Biological Triggers of Evolutionary Conserved Bcl-xL-Mediated Apoptosis. Cancers 2020, 12(6), 1694; https://doi.org/10.3390/cancers12061694

          24. Ianevski A, Yao R, Fenstad MH, Biza S, Zusinaite E, Reisberg T, Lysvand H, Løseth K, Landsem VM, Malmring JF, Oksenych V, Erlandsen SE, Aas PA, Hagen L, Pettersen CH, Tenson T, Afset JE, Nordbø SA, Bjørås M, and Kainov DE (2020) Potential Antiviral Options against SARS-CoV-2 Infection. Viruses 2020, 12(6), 642; https://doi.org/10.3390/v12060642

          23. Andersen PI, Ianevski A, Lysvand H, Vitkauskiene A, Oksenych V, Bjørås M, Telling K, Lutsar I, Dampis U, Irie Y, Tenson T, Kantele A, and Kainov D. E. (2020) Discovery and Development of Safe-In-Man Broad-Spectrum Antiviral Agents. Int J Infect Dis. 2020 Feb 17. PMID: 32081774 https://doi.org/10.1016/j.ijid.2020.02.018

          22*. Castañeda-Zegarra S, Huse C, Røsand Ø, Sarno A, Xing M, Gago-Fuentes R, Zhang Q, Alirezaylavasani A, Werner J, Ji P, Liabakk N, Wang W, Bjørås M, Oksenych V.* (2019) Generation of a Mouse Model Lacking the Non-Homologous End-Joining Factor Mri/Cyren. Biomolecules 9(12), 798

         21*. Xing M, and Oksenych V.* (2019). Genetic interaction between DNA repair factors PAXX, XLF, XRCC4 and protein kinase DNA-PKcs in human cells. FEBS Open Bio. https://doi.org/10.1002/2211-5463.12681

         20*. Castañeda-Zegarra S, Xing M, Gago-Fuentes R, Sæterstad S, Oksenych V.* (2019) Synthetic lethality between DNA repair factors Xlf and Paxx is rescued by inactivation of Trp53. DNA Repair (Amst). 73:164-169. https://doi.org/10.1016/j.dnarep.2018.12.002

       19. Bohl K, Ianevski A, Than TT, Andersen PI, Kuivanen S, Teppor M, Zusinaite E, Dumpis U, Vitkauskiene A, Cox RJ, Kallio-Kokko H, Bergqvist A, Tenson T, Oksenych V, Bjoras M, Anthonsen MW, Shum D, Kaarbo M, Vapalahti O, Windisch MP, Superti-Furga G, Snijder B, Kainov D, Kandasamy R. (2019). Critical Nodes of Virus-Host Interaction Revealed Through an Integrated Network Analysis. Front Immunol. 2019 Oct 4;10:2186. https://doi.org/10.3389/fimmu.2019.02186

       18. Ianevski A, Zusinaite E, Shtaida N, Kallio-Kokko H, Valkonen M, Kantele A, Telling K, Lutsar I, Letjuka P, Metelitsa N, Oksenych V, Dumpis U, Vitkauskiene A, Stašaitis K, Öhrmalm C, Bondeson K, Bergqvist A, Cox RJ, Tenson T, Merits A, Kainov DE. (2019) Low Temperature and Low UV Indexes Correlated with Peaks of Influenza Virus Activity in Northern Europe during 2010⁻2018. Viruses. 11(3). pii: E207. https://doi.org/10.3390/v11030207

          17*. Dewan A, Xing M, Lundbæk MB, Gago-Fuentes R, Beck C, Aas PA, Liabakk NB, Sæterstad S, Chau KTP, Kavli BM, Oksenych V.* (2018). Robust DNA repair in PAXX-deficient mammalian cells. FEBS Open Bio 8(3):442-448

          16*. Gago-Fuentes R, Xing M, Sæterstad S, Sarno A, Dewan A, Beck C, Bradamante S, Bjørås M, Oksenych V.* (2018). Normal development of mice lacking PAXX, the paralogue of XRCC4 and XLF. FEBS Open Bio 8(3):426-434

       15. Ianevski A, Zusinaite E, Kuivanen S, Strand M, Lysvand H, Teppor M, Kakkola L, Paavilainen H, Laajala M, Kallio-Kokko H, Valkonen M, Kantele A, Telling K, Lutsar I, Letjuka P, Metelitsa N, Oksenych V, Bjørås M, Nordbø SA, Dumpis U, Vitkauskiene A, Öhrmalm C, Bondeson K, Bergqvist A, Aittokallio T, Cox RJ, Evander M, Hukkanen V, Marjomaki V, Julkunen I, Vapalahti O, Tenson T, Merits A, Kainov D. (2018). Novel activities of safe-in-human broad-spectrum antiviral agents. Antiviral Research. 154:174-182. https://doi.org/10.1016/j.antiviral.2018.04.016

          14*. Xing M, Bjørås M, Daniel JA, Alt FW, Oksenych V.* (2017) Synthetic lethality between murine DNA repair factors XLF and DNA-PKcs is rescued by inactivation of Ku70. DNA Repair (Amst.) 57: 133-138

       13. Bulanova D, Ianevski A, Bugai A, Akimov Y, Kuivanen S, Paavilainen H, Kakkola L, Nandania J, Turunen L, Ohman T, Ala-Hongisto H, Pesonen HM, Kuisma MS, Honkimaa A, Walton EL, Oksenych V, Lorey MB, Guschin D, Shim J, Kim J, Than TT, Chang SY, Hukkanen V, Kulesskiy E, Marjomaki VS, Julkunen I, Nyman TA, Matikainen S, Saarela JS, Sane F, Hober D, Gabriel G, De Brabander JK, Martikainen M, Windisch MP, Min JY, Bruzzone R, Aittokallio T, Vähä-Koskela M, Vapalahti O, Pulk A, Velagapudi V, Kainov DE. (2017). Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins. Viruses. 9(10). pii: E271. https://doi.org/10.3390/v9100271

          12*(11*). Kumar V, Alt FW, Oksenych V.* (2014) Functional overlaps between XLF and the ATM-dependent DNA double strand break response. DNA Repair (Amst.) 16:11-22 Re-published by the same journal (reprint)

       10. Oksenych V, Zhovmer A, Ziani S, Mari PO, Eberova J, Nardo T, Stefanini M, Giglia-Mari G, Egly JM, Coin F. (2013) Histone methyltransferase DOT1L drives recovery of gene expression after a genotoxic attack. PLoS Genet 9(7):e1003611                                                                                       

       9. Oksenych V, Kumar V, Liu X, Guo C, Schwer B, Zha S, Alt FW. (2013) Functional redundancy between the XLF and DNA-PKcs DNA repair factors in V(D)J recombination and nonhomologous DNA end joining. PNAS 110(6):2234-9

       8. Oksenych V, Alt FW, Kumar V, Schwer B, Wesemann DR, Hansen E, Patel H, Su A, Guo C. (2012) Functional redundancy between repair factor XLF and damage response mediator 53BP1 in V(D)J recombination and DNA repair. PNAS 109(7):2455-60                        

       7#. Boboila C#, Oksenych V#, Gostissa M, Wang JH, Zha S, Zhang Y, Chai H, Lee CS, Jankovic M, Saez LMA, Nussenzweig MC, McKinnon PJ, Alt FW, Schwer B.* (2012) Robust chromosomal DNA repair via alternative end-joining in the absence of X-ray repair cross-complementing protein 1 (XRCC1). PNAS 109(7):2473-8     #co-first

       6. Zha S, Guo C, Boboila C, Oksenych V, Cheng HL, Zhang Y, Wesemann DR, Yuen G, Patel H, Goff PH, Dubois RL, Alt FW. (2011) ATM Damage Response and XLF Repair Factor are Functionally Redundant In Joining DNA Breaks. Nature 469(7329):250-4                                            

       5. Oksenych V, Coin F. (2010) The long unwinding road: XPB and XPD helicases in damaged DNA opening. Cell Cycle 9 (1), 90-96                                                                             

       4.Zhovmer A, Oksenych V, Coin F. (2010) Two sides of the same coin: TFIIH complexes in transcription and DNA repair. The Scientific World JOURNAL 10, 633-643                          

       3. Oksenych V, De Jesus BB, Zhovmer A, Egly JM, Coin F. (2009) Molecular insights into the recruitment of TFIIH to sites of DNA damage. EMBO J 28(19):2971-80                             

       2. Coin F, Oksenych V, Mocquet V, Groh S, Blattner C, Egly JM. (2008) Nucleotide excision repair driven by the dissociation of CAK from TFIIH. Mol Cell 31(1):9-20                                           

       1. Coin F, Oksenych V, Egly JM. (2007) Distinct roles for the XPB/p52 and XPD/p44 subcomplexes of TFIIH in damaged DNA opening during nucleotide excision repair. Mol Cell 26(2):245-56